- Poster presentation
- Open Access
Media and microcarrier surface must be optimized when transitioning mesenchymal stem/stromal cell expansion to stirred tank bioreactors
© Schnitzler et al. 2015
- Published: 14 December 2015
- Suspension Culture
- Stir Tank Bioreactor
- Platelet Lysate
- Spinner Flask
- Large Scale Manufacturing
The long-term outlook for regenerative medicine predicts an increased need for high quality materials that are compatible with the limited number of downstream processing steps required for cell-based therapies. Large scale manufacturing of adherent-dependent cell types necessitates movement away from planar culture and toward technologies such as stirred tank bioreactors where suspension culture using microcarriers is enabled . Microcarriers are available in a variety of base materials including glass, polystyrene or dextran, and have been coated or derivatized to carry charge, peptides or extracellular matrix proteins such as collagen that may be animal-derived. Cell culture medium may also contain animal-derived components. Fetal bovine serum (FBS) in particular is associated with regulatory, supply, and consistency challenges . Eliminating this commonly-used reagent will require thorough evaluation of animal origin-free materials for compatibility with cell therapy applications. Here, we evaluated growth of human mesenchymal stem/stromal cells (MSCs) with a variety of microcarriers and cell culture media formulations. Not only was a wide range of performance observed between the microcarriers and media screened, but positive performance in static culture was not necessarily predictive of that under agitated conditions.
To evaluate different microcarriers, human adipose-derived MSCs (aMSCs) were grown on a panel of microcarriers in Petri dishes, 125 mL spinner flasks, or Mobius® 3 L bioreactors in DMEM supplemented with 10% FBS and 8 ng/mL bFGF (DMEM FBS). TrypLE was used to detach a MSCs from microcarriers to assess recovery.
To evaluate different media formulations, human bone marrow-derived MSCs (bmMSCs) were grown on gelatin-coated T-flasks for planar culture or seeded onto collagen-coated microcarriers in 125 mL spinner flasks for suspension culture. Planar cultures were maintained in respective media from passage 4 to 8. Top performing media were further evaluated in microcarrier-based suspension culture for 7 days. Serum (DMEMFBS) control flasks were run in parallel.
Cell were seeded at 3k cells / cm2 and 5.4 cm2 / mL of culture surface was provided in all microcarrier experiments. Nexcelom Cellometer® and NucleoCounter® devices were used for cell counting.
Expansion of aMSCs with various microcarriers in static or agitated small scale platforms.
Day 7 fold increase
Overall cell yield (E+04 cells / mL)
The observation that some microcarriers and cell culture media that support robust MSC growth in static or planar culture do not perform in microcarrier-based suspension culture highlights the complex interaction between culture surface, media formulation and hydrodynamic forces introduced by agitation. Small scale platforms such as Petri dishes and spinner flasks are convenient tools for initial screening of many microcarriers or media, but a sufficient number of top performers need to be moved into bioreactor suspension culture for further evaluation. A better understanding of the underlying biological requirements of adherent-dependent cells in suspension culture will foster the development of high quality reagents that support expansion across platforms. The combination of serum-free systems with animal origin-free materials will be required to support the future implementation of large scale manufacturing solutions following clinical success of cell-based therapies.
- Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS: Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng. 2014, 111: 69-83.PubMedPubMed CentralView ArticleGoogle Scholar
- Brindley DA, Davie NL, Culme-Seymour EJ, Mason C, Smith DW, Rowley JA: Peak serum: implications of serum supply for cell therapy manufacturing. Regen Med. 2012, 7: 7-13.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.